SlideShare una empresa de Scribd logo
1 de 67
Descargar para leer sin conexión
DRUG USES IN SPECIAL CASES
DR.AKSHIL MEHTA
Drug Use During Pregnancy
Drug use during Pregnancy
• Every system in the body is affected by
pregnancy
• Pharmacokenetics & pharmacodynamics of
drugs is affected by pregnancy
• At present these pharmacokinetic factors are
beginning to be understood whereas
pharmacodynamics information is still
incomplete
3
• 1. Absorption: ↑ed
 Gastric emptying time is delayed & gut motility
reduced because of ↑ed progesterone
 Vasodilation , tissue perfusion ↑ed
• 2. Distribution: ↑ed
 Total body water increases i.e. hemodilution
 Plasma albumin conc. ↓ed so ↑ed free drug
conc.
 Increased body fat, reservoir of lipid soluble drug
Pharmacokenetics Of Drugs During
Pregnancy
4
• 3. Metabolism:
 hepatic metabolism increases but no altered
hepatic blood flow
• 4. Elimination:
 Renal blood flow doubles, so rapid
elimination of drugs excreted by kidney
(e.g.Aminoglycosides)
 Dose should be increased in such cases
Pharmacokenetics Of Drugs During
Pregnancy
5
Factors Affecting Placental Drug
Transfer & Subsequent Effect On Fetus
1. Physiochemical properties of the drug
2. Rate at which drug crosses placenta & amount
reaching the fetus
3. Duration of exposure to drug
4. Distribution characteristics of drug in different
fetal tissues
5. Stage of placental & fetal development at the
time of exposure
6. Effects of drugs used in combination
6
A. Lipid solubility
Lipophilic drugs crosses placenta more
e.g.thiopental may cause apnoea in fetus,
salicylate is ionised but very lipid soluble
B. Molecular size & pH
250-500 easily
500-1000 with difficulty
>1000 poorly
maternal blood pH 7.4 & fetal 7.3 , may lead to ion
trapping in c/o pKa >7.4
C. Placental transporters
e.g. P glycoprotein transporter encoded by MDR1
gene pumps back some drugs like cancer drugs
(doxorubicin)
and viral protease inhibitors
7
D. Protein binding
more protein bound drug crosses less
doesn’t affect lipid soluble drug that much
differential protein binding – Glyburide
E. Placental & fetal drug metabolism
1) Placenta: aromatic oxidation reactions occur
e.g. Phenobarbital
may also lead to toxic metabolite e.g. ethanol,
benzpyrenes
2) Fetus: 40-60% blood enters fetal liver
a proportion of blood is shunted back
through placenta
8
Pharmacodynamics
A. Maternal Drug Actions
• Effect on reproductive tissue may be altered
by endocrinal environment due to pregnancy
• Effect on other tissues not changed much
• Altered physiologic context may require
treatment
e.g. cardiac glycosides & diuretics for heart
failure , insulin for pregnancy induced
diabetes
9
B. Therapeutic Drug Actions In The Fetus
emerging area ‘ Fetal Therapeutics’
i. Corticosteroids: e.g. dexamethasone for lung
maturation in premature labour
ii. Phenobarbitone: for neonatal jaundice or
decrease intra cranial bleeding
iii. Zidovudine or nevirapine: alone or in
combination to prevent vertical transmission
Pharmacodynamics
10
Toxic Effects Of Drugs On The Embryo,
Fetus, Or Neonate
May vary
• No effect.
• Little
• Serious- fetal toxicity
• Spontaneous abortion
• Death
• Fetal malfunction
• Fetal malformations.
11
C. Predictable Toxic Effects
i. Opioids : dependance , neonatal withdrawal
syndrome, respiration depression
ii. ACE inhibitors : renal damage
iii. Diethylstilbestrol: adenocarcinoma of vagina
after puberty
Pharmacodynamics
12
D. Teratogenic Drug Actions:
Birth Defects
• Incidence of major structural
defects(abnormalities) is about 6% of all
pregnancies.
• 3% are caused by drugs or environmental
factors/exposure
• 3% have a genetic or unknown causes
Pharmacodynamics
13
• 1/2 of the birth defects are obvious at birth.
• 1/2 of the birth defects aren’t discovered until
later in life or discovered during an autopsy
• Incidence of minor structural anomalies is not
known.
• Incidence of functional abnormalities is not
known-growth restrictions, mental
retardation, and learning disabilities
• Some abnormalities have multiple causes-
genetic factors, environmental factors,
chemicals or drugs.
14
Teratogenic
Teratogenesis
• Teras-”monster”
• Gensis-”producing”
• Birth defects/distortion of gross anatomy.
• Examples- cleft lip/palate, clubfoot, neural tubal
defects, missing or malformed limbs/fingers.
• Now also- behavioral and/ or biochemical and/or
physiological abnormalities.
• Death of fetus & carcinogenic effect
15
Mechanism of Teratogenesis
• Direct effect on maternal tissue with secondary
effect on fetus
• Indirect-such as interfering with o2 or nutrients.
• Teratogenesis maybe direct-malformations of
structures. e.g.
i. Vitamin A analogs (isotretinoin,etretinate)
ii. Deficiency of a critical substance (folic acid
causing neural tube defects)
iii. Continues exposure to teratogen may produce
cumulative effect (Fetal Alcohol Syndrome)
16
Proving A Drug Is A Teratogen
3 Criteria must be met:
• 1. Drug must cause a characteristic set of
malformations with selectivity for certain
organs
• 2. It must act only during a specific window of
vulnerability (organogenesis of target organ)
• 3. The incidence of malformations should
increase with increased dosage & duration of
exposure.
17
Fetal Effects From Drugs Depend On
Several Factors
• Time- when drug is taken in pregnancy.
• Preimplantation/presomite period-
conception to 2 week
• High dose- maybe lethal/death/abortions.
• Low dose-maybe nothing.
As per time …..
18
① 0-2 weeks-period of dividing zygote ,
implantation
• Prenatal death may occur
• Abortion may occur due to oxytosics e.g. ergot
alkaloids, anti metabolites
② Embryonic period-3-8 weeks - First trimester
• Gross malformations
• E.G. One time exposure to thalidomide through
4th to 7th week-causes missing limbs(phocomalia).
③Fetal period-9-40 weeks(term)
• Function problems rather than gross anatomy
• Learning deficits &/or behavioral abnormalities
19
20
21
22
• ④Late pregnancy
23
• ⑤ During labor
24
Others such as
• Thrombocytopenia due to sensitization by
thiazide diuretics when given to mother
• Mercury may cause impaired brain
development , cerebral palsy, mental
retardation etc.
• Other fetal defects due to effect of drug on
spermatogenesis are suspected
25
Why is identification of teratogenic
agents sometimes difficult to
identify?
• Incidence of congenital anomalies is generally
low.
• Animal tests may not be reliable
• Prolonged or increased exposure maybe
required.
• Effects maybe delayed or not reconized.
• Behavioral effects are difficult to document.
• Controlled experiments cannot be done on
humans.
26
• Documentation is incomplete
• Only in a limited number of drugs is the
teratogenic effects known or proven.
• Lack of proof of teratogenicity does not
mean a drug is safe in pregnancy
• May mean there is a lack of research or
information.
27
How Is Data Collected On Drugs
Which Cause Problems In
Pregnancies?
• No human experimentation
• Systematic collection and analyzing of data
on drugs taken by pregnant clients.
• Reporting of information by health
professionals.
28
FDA category of drugs used in
pregnancy
29
Precautions While Prescribing During
Reproductive Age & Pregnancy
1. In c/o contraception failure – Explain risk of drug
already received & to continue pregnancy or
abort
2. Similarly, in c/o post coital contraception
3. If a woman is being treated , explain risks to
fetus & advise to avoid pregnancy till therapy
completes
4. If a woman of reproductive age comes with any
ailment pregnancy should be ruled out & then
follow guideline as shown next
30
A. If not pregnant
i) Conception not desired : normal treatment
ii) Conception desired:
• Advise not to take any medication after last
menstrual period
• Advise folic acid & iron supplements
• If diabetic start her on insulin
• Avoid self treatment if ill, consult doctor
31
B. If pregnant
• Advise same as 4.A.ii in last slide
• Avoid use of drug & treat minor problems
without drugs
• Strictly avoid proven teratogens i.e. Cat. X & D
• If required prescribe proven safe drug
• Use minimal dose for shortest period of time
• If an unsafe or unproven drug has to be used
than do α-fetoproteins at 16 weeks of
gestation & high quality ultrasound at 18
weeks to asses anomalies
32
Education Of Pregnant/Pre-pregnant
• Provide accurate information with rationales
• Information should be current and based on evidence.
• Establish environment conducive to exchange of
information - trust.
• Potential harm/risks. Common substances & OTC drugs
to avoid in pregnancy- ASA, alcohol, increased doses of
multivitamins, caffeine, cigarette smoking, etc.
• Avoid self treatment – OTCs
• Support
• Assist with coping if woman has taken a teratogenic
agent..With guilt or fear…associated with drugs taken in
pregnancy.
33
Common Medications Safe In
Pregnancy
1.GIT conditions:
a) Nausea & vomiting:
pyridoxine with or without doxylamine,
meclizine, cyclizine, diphenhydramine
Avoid- neuroleptics , metochlorpromide (safe in
3rd trimester)
b) Constipation:
mild purgative , lubricant purgative (less safe)
Avoid- strong purgative as may cause abortion
or premature labor pain
34
c) Heart burn:
milk of magnesia
Avoid- anticholinergics
d) Peptic ulcer:
sucralfate, bismuthsubcitrate & H2 blockers
2.Hemopoetic
Iron, folic acid
no role of vit.B12
35
3.Infections
a) Bacterial:
i. UTI
ampicillin, amoxycillin, cephalexin, cefadroxil,
cefuroxime etc.
Avoid-fluoroquinolones
ii. Other
β-lactum antibiotics (penicillin G, penicillin
V), ampicillin, amoxycillin, cloxacillin) ,
cephalosporins (cephalexim, cefadroxil,
cefuroxime, ceftriaxone) ,
macrolides(erythromycin avoid estolate salt,
azithromycin).
36
gentamycin & tobramycin only if serious
infection
b) Malaria:
chloroquine, quinine (higher dose may induce
labor), proguanil, pyrimethamine (with folic
acid)
c) Amoebiasis:
metronidazole, diloxanide (avoid single large
dose)
d) Worm infestations:
piperazine citrate, pyrantel pamoate,
bephenium hydroxynaphthoate, praziquintal
(teratogenic in animals not in humans)
37
e) Fungal infections:
miconazole, clotrimazole & nystatin
f) HIV infection:
none are safe but zidovudine and nevirapine
are given to prevent vertical transmission
g) Tuberculosis:
INH and ethambutol, if 3rd needed rifampicin,
pyrazinamide only in severe cases like
meningitis
38
4. Endocrine disorders
a) Diabetes mellitus:
always use insulin
b) Hypothyroidism:
thyroxine
c) Thyrotoxicosis:
propylthiouracil
d) Corticosteroid are highly teratanogenic and
must be avoided
39
5. Cardiovascular disorders
a) Hypertension:
α-methyl dopa oral & hydralazine in
emergency
β blocker like labetolol (also can be given
i.v.), atenolol
b) Thromboembolic disease:
LMWH (note just before labor)
Avoid- warfarin
40
6. CNS disorders
a) General anesthetics:
thiopentone sodium & nitrous oxide
b) Headache & Inflammation:
paracetamol, codeine preparation
Avoid- other NSAIDS
aspirin can be used in lowest doses upto 2 weeks
before EDD
c) Epilepsy:
Avoid-Na valproate, phenytoin
d) Migraine:
paracetamol, propranolol, amitryptyline
41
e) Sedative :
benzodiazepine; e.g. diazepam
f) Antidepressant:
amitryptyline, imipramine
Avoid- Lithium (fetal cardiac anomalies)
7. Respiratory problems
a) cough:
codeine, dexomethorphan
b) Bronchial asthma:
β2 agonists (e.g. salbutamol), aminophyline,
disodium cromoglycate
42
8. Others
a) Corticosteroids must be avoided except at
term for lung maturation with tocolytics
b) Fat soluble vitamins may cause subaortic
stenosis & craniofacial anomalies , so avoid
c) Vaccines: only T.T. ; avoid live vaccines
d) avoid indigenous drugs
43
Drug Use During Lactation
• Most drugs are excreted into breast milk
• But they are less quantity
• Because of large volume of distribution in
mother’s body compared to small amount of
milk
• Lipophilic drugs are readily excreted also non
plasma protein bound
• pH of milk = 7.0 , slightly acidic
• Mainly transported by passive diffusion
• Adverse reaction in fetus due to
i. slower elimination ( more accumulation)
ii. Sensitive & idiosyncratic reaction
45
• TRH & metochlorpramide ↑es lactation
• Ergotamine & bromocriptine ↓es lactation
used in loss of fetus or newborn & in
hyperprolactinaemia
• Most of the drugs & vaccines are safe
• Drugs which are to be avoided or monitored
are discribed next
46
Drugs used during lactation & possible side effects 47
Drug Use In Infants & Children
Pharmacokinetics in Children
1. Absorption
a. ↑ from skin due to thin stratum corneum & better
hydration
b. GIT: altered, low acidity, ↑ed gastric emptying time,
↑ed enterohepatic circulation, irregular
peristalsis(PCM & phenobarbitone ↓ed & of penicillin
G & ampicillin ↑ed )
c. Intramuscular & subcutaneous unpredictable
because thin skeletal muscle mass & fat
d. Low bile acid & lipase so less lipophilic drug
absorption
e. diarrhoea
49
2. Drug distribution
a. More in c/o hydrophilic than adult because of
higher percentage of body water (65-85%), also
40% is extra cellular in the neonate
(aminogycoside)
b. Less fat in pre term (1% ) than full term(15%)
thus less lipophilic drug concentration in
premature
c. Less plasma protein available so more free drug ,
so more toxicity (diazepam)
d. Competition with bilirubin for albumin may
displace it , may cause kernicterus
(sulfonamides) & vice versa (phenytoin)
50
3. Drug metabolism
a. Less liver cytochrome P450 dependent activity , so
chances of toxicity high e.g.chloramphenicol
causing grey baby syndrome
b. Table shows
difference in half life in
Neonate & adult
p.s.phenobarbital &
Phenytoin have low half
life during infancy
51
c. Enzyme induction
Due to mother receiving drugs or child
-enzyme induction may increase interaction
-phenobarbitone is used to treat neonatal
jaundice on the same principal
* During toddlerhood metabolite rate of many
drugs exceeds adult values .
52
4. Drug excretion
a. GFR is less , so is tubular secretion, resulting
in less renal clearance
b. Normal clearance achieved at the age of 6-12
months
c. Subsequently during toddlerhood it increases
than adult value for some (e.g. for digoxin)
d. So appropriate dose adjustment is necessary
e. E.g. penicillin, ampicillin, aminoglycosides
53
Pharmacodynamic alterations
• Response of drug may be different in children
than adults but mechanism remain same
• Due to immature receptors or
neurotransmitter system
• e.g. glucocorticoids-premature epiphysial
fusion; tetracyclines- malformed bone & teeth
also staining of teeth, antihistaminics &
barbiturates –excitement, amphetamine- ↓es
abnormal hyperactivity
54
Clinically important
PDA can be closed with administration of
indomethacin
In case of fallot’s tetralogy administration of
alprostadil (PGE1) is life saving
55
Pediatric Dosage Forms & Compliance
• Use of tablets is inconvenient & injections are
rejected by children
• So preferred formulations are liquid e.g.
suspension, elixir, drops
• Proper use should be instructed
• Rejection, spitting & vomiting should be
considered
• Proper measurement
• Suspensions to be shaken well before use
• Reduce dosing errors
• Encourage children to take medicine themselves
56
Dose
• Young’s rule: dose= Adult dose × Age(years) /
Age + 12
• Clark’s rule: dose = Adult dose × Weight(kg) /
70
• Determination of
drug dosage from
surface area
57
Drug Use In Geriatric Patients
Geriatric (>65 years) patients have more
chances of drug interactions & ADRs
1. Presence of multiple disease (avg. 5-8 drugs)
2. Sluggishness of various body functions
3. Reduced healthcare finance
4. Nutritional problem
5. Loss of spouse
6. Poor patient compliance due to poor
understanding, confusion, forgetfulness, poor
hearing, poor vision, physical disability
7. Pharmacological changes due to ageing
59
Pharmacokinetic Changes
a) Absorption
• Slow due to ↓ed blood flow , ↓ed motility
• Altered nutrition
• Multiple OTCs
b) Distribution
• Reduced body weight
• ↓ed body water, ↑ed body fat, ↓ed plasma
proteins
• So more free drug
60
c) Biotransformation
• ↓ed due to less liver mass, blood flow & reduced
ability to recover from injury so
• Phase I inactivation reduced by microsomal
mixed function oxidases
• No change in phase II reaction
• Extensively first pass metabolized drug will have
higher than normal conc. E.g. TCAs, neuroleptics,
antidysrhythmic drugs
• Less induction of hepatic microsomal enzyme so
less interaction through there
• Malnutrition & other diseases
61
d) Excretion
• ↓ed GFR, ↓ed tubular secretion,
• No s.creat ↑ though, due to less muscle mass
• Narrow therapeutic window drugs show
toxicity e.g. lithium, digoxin, atenolol
• Decrease respiratory capacity & more lung
diseases so less excretion through lungs e.g.
general anesthetics
• Creat cl (ml/min)= (140-Age)×(weight kg)
72 × s.creat(mg/dl)
62
Pharmacodynamic changes
a) Response is decreased e.g. β agonists & β blockers ,
due to ↓ed no. of receptors
b) Response is increased
• More chance of postural/orthostatic hypotension due
to reduced baroreceptor sensitivity
• Drugs acting on CNS (like sedative-hypnotics) shows
more response, more respiratory depression
• Intolerance to digitalis & neuroleptic
C) Drugs with anticholinergic activity may cause
retention in elderly with BPH
• Average BP increases
• Temperature regulation is impaired
63
Precautions While Prescribing To Elderly
1. Make sure of diagnosis & reuirement
2. Prescribe drug with minimal side effects
3. Prescribe minimum number of drugs (brown bag
analysis)
4. Dose adjustment to minimal & mind hepatic or
renal damage
5. Use suitable dosage form
6. Readable label , easy packing
7. ADR
8. Drug history including OTCs & herbal
64
9. Use FDCs where appropriate
10. Avoid drug interactions
11. Patient compliance
12. Discontinuation of drug is as important as
starting , e.g. withdrawal syndromes, relapse
of infection
65
References
• Basic and clinical pharmacology by Dr. Bertram
G Katzung et al 12th edition
• A complete textbook of medical pharmacology
vol.II by Dr. S K Srivastava
• Goodman and Gilman's The Pharmacological
Basis of Therapeutics (12th Edition)
• www.cdc.gov/media/dpk/2013/docs/dpk-
safe-meds-doc1.pdf
66
67

Más contenido relacionado

La actualidad más candente

Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure Mallinath Paramgond
 
SOFTWARE USED IN P'epidemiology.pdf
SOFTWARE USED IN P'epidemiology.pdfSOFTWARE USED IN P'epidemiology.pdf
SOFTWARE USED IN P'epidemiology.pdfvarshawadnere
 
Effects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsEffects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsDr. Ramesh Bhandari
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsViraj Shinde
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimenDr. Ramesh Bhandari
 
Drug interactions their types, examples and role
Drug interactions their types, examples and roleDrug interactions their types, examples and role
Drug interactions their types, examples and roleYousra Ashraf
 
b. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxb. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxAnusha Are
 
Drugs used in pregnancy and lactation
Drugs used in pregnancy and lactationDrugs used in pregnancy and lactation
Drugs used in pregnancy and lactationKoppala RVS Chaitanya
 
Inhibition and induction of drug metabolism
Inhibition and induction of drug metabolismInhibition and induction of drug metabolism
Inhibition and induction of drug metabolismDr. Ramesh Bhandari
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersAbel C. Mathew
 
Dose adjustment in renal disease
Dose adjustment in renal diseaseDose adjustment in renal disease
Dose adjustment in renal diseaseAreej Abu Hanieh
 
Pharm d research project
Pharm d research projectPharm d research project
Pharm d research projectSai Kumar
 
Therapeutic drug monitoring ppt
Therapeutic drug monitoring pptTherapeutic drug monitoring ppt
Therapeutic drug monitoring pptPARUL UNIVERSITY
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
 

La actualidad más candente (20)

Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Dose adjustment in Renal failure
Dose adjustment in Renal failure Dose adjustment in Renal failure
Dose adjustment in Renal failure
 
SOFTWARE USED IN P'epidemiology.pdf
SOFTWARE USED IN P'epidemiology.pdfSOFTWARE USED IN P'epidemiology.pdf
SOFTWARE USED IN P'epidemiology.pdf
 
Effects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsEffects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokinetics
 
Drug interactions
Drug interactions Drug interactions
Drug interactions
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patients
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
 
Drug interactions their types, examples and role
Drug interactions their types, examples and roleDrug interactions their types, examples and role
Drug interactions their types, examples and role
 
b. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptxb. Clinical Pharmacy.pptx
b. Clinical Pharmacy.pptx
 
Ad rs ppt
Ad rs pptAd rs ppt
Ad rs ppt
 
Drug information resources
Drug  information resourcesDrug  information resources
Drug information resources
 
Drugs used in pregnancy and lactation
Drugs used in pregnancy and lactationDrugs used in pregnancy and lactation
Drugs used in pregnancy and lactation
 
Inhibition and induction of drug metabolism
Inhibition and induction of drug metabolismInhibition and induction of drug metabolism
Inhibition and induction of drug metabolism
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
 
Dose adjustment in renal disease
Dose adjustment in renal diseaseDose adjustment in renal disease
Dose adjustment in renal disease
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Prescription Patterns
Prescription PatternsPrescription Patterns
Prescription Patterns
 
Pharm d research project
Pharm d research projectPharm d research project
Pharm d research project
 
Therapeutic drug monitoring ppt
Therapeutic drug monitoring pptTherapeutic drug monitoring ppt
Therapeutic drug monitoring ppt
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.
 

Destacado

Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyRoopali Somani
 
Drugs used in pregnancy
Drugs used in pregnancyDrugs used in pregnancy
Drugs used in pregnancyethan1hunt
 
Pregnancy and lactation
Pregnancy and lactationPregnancy and lactation
Pregnancy and lactationTsegaye Melaku
 
DRUGS IN PREGNANCY
 				DRUGS IN PREGNANCY 				DRUGS IN PREGNANCY
DRUGS IN PREGNANCYgolden4host
 
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & LactationPK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & LactationSreeja Saladi
 
Pharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancyPharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancyReem Alyahya
 
Polypharmacy in the elderly
Polypharmacy in the elderlyPolypharmacy in the elderly
Polypharmacy in the elderlyMarc Evans Abat
 
Medications during pregnancy
Medications during pregnancyMedications during pregnancy
Medications during pregnancyDr. Salman Iqbal
 
Pharmacokinetics In Special Populations
Pharmacokinetics In Special PopulationsPharmacokinetics In Special Populations
Pharmacokinetics In Special Populationspccampo
 
Drugs in pregnency
Drugs in pregnencyDrugs in pregnency
Drugs in pregnencyhome
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014vanessawhitehawk
 
Prescribing medication for the elderly
Prescribing medication for the elderlyPrescribing medication for the elderly
Prescribing medication for the elderlyAbdalla Ibrahim
 
pediatric Drug administration
pediatric Drug administrationpediatric Drug administration
pediatric Drug administrationRia Saira
 
drugs in pregnancy
 drugs in pregnancy drugs in pregnancy
drugs in pregnancymt53y8
 
Prescribing guidelines for pregnancy and lactation by Dr.Prudhvi
Prescribing guidelines for pregnancy and lactation by Dr.PrudhviPrescribing guidelines for pregnancy and lactation by Dr.Prudhvi
Prescribing guidelines for pregnancy and lactation by Dr.Prudhvivallampati prudhvi
 

Destacado (20)

Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancy
 
Pediatric Medication
Pediatric MedicationPediatric Medication
Pediatric Medication
 
Drugs used in pregnancy
Drugs used in pregnancyDrugs used in pregnancy
Drugs used in pregnancy
 
Pregnancy and lactation
Pregnancy and lactationPregnancy and lactation
Pregnancy and lactation
 
DRUGS IN PREGNANCY
 				DRUGS IN PREGNANCY 				DRUGS IN PREGNANCY
DRUGS IN PREGNANCY
 
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & LactationPK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
PK and Drug Therapy in pediatrics, geriatrics and pregnancy & Lactation
 
Pharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancyPharmacodynamics and kinetics during pregnancy
Pharmacodynamics and kinetics during pregnancy
 
Polypharmacy in the elderly
Polypharmacy in the elderlyPolypharmacy in the elderly
Polypharmacy in the elderly
 
Medications during pregnancy
Medications during pregnancyMedications during pregnancy
Medications during pregnancy
 
Specific issues in drug use and pregnancy
Specific issues in drug use and pregnancySpecific issues in drug use and pregnancy
Specific issues in drug use and pregnancy
 
Drug use in pregnany
Drug use in pregnanyDrug use in pregnany
Drug use in pregnany
 
Pharmacokinetics In Special Populations
Pharmacokinetics In Special PopulationsPharmacokinetics In Special Populations
Pharmacokinetics In Special Populations
 
Drugs in pregnency
Drugs in pregnencyDrugs in pregnency
Drugs in pregnency
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014
 
Prescribing medication for the elderly
Prescribing medication for the elderlyPrescribing medication for the elderly
Prescribing medication for the elderly
 
pediatric Drug administration
pediatric Drug administrationpediatric Drug administration
pediatric Drug administration
 
Drug Calculation
Drug CalculationDrug Calculation
Drug Calculation
 
drugs in pregnancy
 drugs in pregnancy drugs in pregnancy
drugs in pregnancy
 
Pharmacotherapeutics in obstetrics
Pharmacotherapeutics in obstetricsPharmacotherapeutics in obstetrics
Pharmacotherapeutics in obstetrics
 
Prescribing guidelines for pregnancy and lactation by Dr.Prudhvi
Prescribing guidelines for pregnancy and lactation by Dr.PrudhviPrescribing guidelines for pregnancy and lactation by Dr.Prudhvi
Prescribing guidelines for pregnancy and lactation by Dr.Prudhvi
 

Similar a Drug uses in special physiology( pregnancy , lactation, infant , children, geriatric )

VAriability of drug responses for 4th year.pdf
VAriability of drug responses for 4th year.pdfVAriability of drug responses for 4th year.pdf
VAriability of drug responses for 4th year.pdfRanveerKumarVerma
 
Drug therapy in Pregnancy
Drug therapy in PregnancyDrug therapy in Pregnancy
Drug therapy in PregnancyDr Manju prasad
 
Pharmacotherapy in specific patient groups 2011.pptx
Pharmacotherapy in specific patient groups 2011.pptxPharmacotherapy in specific patient groups 2011.pptx
Pharmacotherapy in specific patient groups 2011.pptxAbdiIsaq1
 
Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyTeratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyabhishekbharti51
 
Drugs use in pregnancy
Drugs use in pregnancyDrugs use in pregnancy
Drugs use in pregnancyVikas Sharma
 
Drug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptxDrug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptxindiarto1
 
Maternal drug intake and breastfeeding
Maternal drug intake and breastfeedingMaternal drug intake and breastfeeding
Maternal drug intake and breastfeedingPriyanka Gohil
 
pharmacotherapeutics in obstetrics. ppt
pharmacotherapeutics  in obstetrics. pptpharmacotherapeutics  in obstetrics. ppt
pharmacotherapeutics in obstetrics. pptFaraBegum
 
Drug therapy in pregnancy
Drug therapy in pregnancyDrug therapy in pregnancy
Drug therapy in pregnancyjaharlal baidya
 
Issues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patientsIssues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patientssamthamby79
 
Introduction to pharmacology
Introduction to pharmacologyIntroduction to pharmacology
Introduction to pharmacologyAfkar432
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptxBAPIRAJU4
 
Repro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdfRepro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdfSanjayaManiDixit
 
Drugs in pregnancy
Drugs in pregnancyDrugs in pregnancy
Drugs in pregnancyredbaron_ad
 
Pharmacology part 5 (pregnancy)
Pharmacology part 5 (pregnancy)Pharmacology part 5 (pregnancy)
Pharmacology part 5 (pregnancy)NkosinathiManana2
 
9 Pregnancy and Lactation.pptx
9 Pregnancy and Lactation.pptx9 Pregnancy and Lactation.pptx
9 Pregnancy and Lactation.pptxSani42793
 

Similar a Drug uses in special physiology( pregnancy , lactation, infant , children, geriatric ) (20)

VAriability of drug responses for 4th year.pdf
VAriability of drug responses for 4th year.pdfVAriability of drug responses for 4th year.pdf
VAriability of drug responses for 4th year.pdf
 
Drug therapy in Pregnancy
Drug therapy in PregnancyDrug therapy in Pregnancy
Drug therapy in Pregnancy
 
Pharmacotherapy in specific patient groups 2011.pptx
Pharmacotherapy in specific patient groups 2011.pptxPharmacotherapy in specific patient groups 2011.pptx
Pharmacotherapy in specific patient groups 2011.pptx
 
Teratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancyTeratogenecity & Safety of drugs in pregnancy
Teratogenecity & Safety of drugs in pregnancy
 
Drugs use in pregnancy
Drugs use in pregnancyDrugs use in pregnancy
Drugs use in pregnancy
 
Drug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptxDrug Prescribing in Pregnancy.pptx
Drug Prescribing in Pregnancy.pptx
 
Maternal drug intake and breastfeeding
Maternal drug intake and breastfeedingMaternal drug intake and breastfeeding
Maternal drug intake and breastfeeding
 
Drug use in pregnancy and lactation (1)
Drug use in pregnancy and lactation (1) Drug use in pregnancy and lactation (1)
Drug use in pregnancy and lactation (1)
 
Drug use in pregnancy and lactation part 1
Drug use in pregnancy and lactation part 1Drug use in pregnancy and lactation part 1
Drug use in pregnancy and lactation part 1
 
pharmacotherapeutics in obstetrics. ppt
pharmacotherapeutics  in obstetrics. pptpharmacotherapeutics  in obstetrics. ppt
pharmacotherapeutics in obstetrics. ppt
 
Drug therapy in pregnancy
Drug therapy in pregnancyDrug therapy in pregnancy
Drug therapy in pregnancy
 
Issues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patientsIssues to consider while prescribing for pregnant and lactating patients
Issues to consider while prescribing for pregnant and lactating patients
 
Introduction to pharmacology
Introduction to pharmacologyIntroduction to pharmacology
Introduction to pharmacology
 
Presentation1.pptx
Presentation1.pptxPresentation1.pptx
Presentation1.pptx
 
8. Teratology.pptx
8. Teratology.pptx8. Teratology.pptx
8. Teratology.pptx
 
Repro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdfRepro-Drugs_in_Pregnancy.pdf
Repro-Drugs_in_Pregnancy.pdf
 
Paediatrics
PaediatricsPaediatrics
Paediatrics
 
Drugs in pregnancy
Drugs in pregnancyDrugs in pregnancy
Drugs in pregnancy
 
Pharmacology part 5 (pregnancy)
Pharmacology part 5 (pregnancy)Pharmacology part 5 (pregnancy)
Pharmacology part 5 (pregnancy)
 
9 Pregnancy and Lactation.pptx
9 Pregnancy and Lactation.pptx9 Pregnancy and Lactation.pptx
9 Pregnancy and Lactation.pptx
 

Más de Akshil Mehta

Structure activity relation ship
Structure activity relation shipStructure activity relation ship
Structure activity relation shipAkshil Mehta
 
Emetics ,antiemetics, prokinetics
Emetics ,antiemetics, prokineticsEmetics ,antiemetics, prokinetics
Emetics ,antiemetics, prokineticsAkshil Mehta
 
Antipsychotic Agents
Antipsychotic AgentsAntipsychotic Agents
Antipsychotic AgentsAkshil Mehta
 
Drug use in hepatic and renal impairment
Drug use in hepatic and renal impairmentDrug use in hepatic and renal impairment
Drug use in hepatic and renal impairmentAkshil Mehta
 
Evaluation of anti epileptic drugs practical
Evaluation of anti epileptic drugs practicalEvaluation of anti epileptic drugs practical
Evaluation of anti epileptic drugs practicalAkshil Mehta
 

Más de Akshil Mehta (7)

Structure activity relation ship
Structure activity relation shipStructure activity relation ship
Structure activity relation ship
 
Emetics ,antiemetics, prokinetics
Emetics ,antiemetics, prokineticsEmetics ,antiemetics, prokinetics
Emetics ,antiemetics, prokinetics
 
Antipsychotic Agents
Antipsychotic AgentsAntipsychotic Agents
Antipsychotic Agents
 
Drug use in hepatic and renal impairment
Drug use in hepatic and renal impairmentDrug use in hepatic and renal impairment
Drug use in hepatic and renal impairment
 
Asthma
AsthmaAsthma
Asthma
 
Evaluation of anti epileptic drugs practical
Evaluation of anti epileptic drugs practicalEvaluation of anti epileptic drugs practical
Evaluation of anti epileptic drugs practical
 
Diarrhoea lecture
Diarrhoea lectureDiarrhoea lecture
Diarrhoea lecture
 

Último

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 

Último (20)

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 

Drug uses in special physiology( pregnancy , lactation, infant , children, geriatric )

  • 1. DRUG USES IN SPECIAL CASES DR.AKSHIL MEHTA
  • 2. Drug Use During Pregnancy
  • 3. Drug use during Pregnancy • Every system in the body is affected by pregnancy • Pharmacokenetics & pharmacodynamics of drugs is affected by pregnancy • At present these pharmacokinetic factors are beginning to be understood whereas pharmacodynamics information is still incomplete 3
  • 4. • 1. Absorption: ↑ed  Gastric emptying time is delayed & gut motility reduced because of ↑ed progesterone  Vasodilation , tissue perfusion ↑ed • 2. Distribution: ↑ed  Total body water increases i.e. hemodilution  Plasma albumin conc. ↓ed so ↑ed free drug conc.  Increased body fat, reservoir of lipid soluble drug Pharmacokenetics Of Drugs During Pregnancy 4
  • 5. • 3. Metabolism:  hepatic metabolism increases but no altered hepatic blood flow • 4. Elimination:  Renal blood flow doubles, so rapid elimination of drugs excreted by kidney (e.g.Aminoglycosides)  Dose should be increased in such cases Pharmacokenetics Of Drugs During Pregnancy 5
  • 6. Factors Affecting Placental Drug Transfer & Subsequent Effect On Fetus 1. Physiochemical properties of the drug 2. Rate at which drug crosses placenta & amount reaching the fetus 3. Duration of exposure to drug 4. Distribution characteristics of drug in different fetal tissues 5. Stage of placental & fetal development at the time of exposure 6. Effects of drugs used in combination 6
  • 7. A. Lipid solubility Lipophilic drugs crosses placenta more e.g.thiopental may cause apnoea in fetus, salicylate is ionised but very lipid soluble B. Molecular size & pH 250-500 easily 500-1000 with difficulty >1000 poorly maternal blood pH 7.4 & fetal 7.3 , may lead to ion trapping in c/o pKa >7.4 C. Placental transporters e.g. P glycoprotein transporter encoded by MDR1 gene pumps back some drugs like cancer drugs (doxorubicin) and viral protease inhibitors 7
  • 8. D. Protein binding more protein bound drug crosses less doesn’t affect lipid soluble drug that much differential protein binding – Glyburide E. Placental & fetal drug metabolism 1) Placenta: aromatic oxidation reactions occur e.g. Phenobarbital may also lead to toxic metabolite e.g. ethanol, benzpyrenes 2) Fetus: 40-60% blood enters fetal liver a proportion of blood is shunted back through placenta 8
  • 9. Pharmacodynamics A. Maternal Drug Actions • Effect on reproductive tissue may be altered by endocrinal environment due to pregnancy • Effect on other tissues not changed much • Altered physiologic context may require treatment e.g. cardiac glycosides & diuretics for heart failure , insulin for pregnancy induced diabetes 9
  • 10. B. Therapeutic Drug Actions In The Fetus emerging area ‘ Fetal Therapeutics’ i. Corticosteroids: e.g. dexamethasone for lung maturation in premature labour ii. Phenobarbitone: for neonatal jaundice or decrease intra cranial bleeding iii. Zidovudine or nevirapine: alone or in combination to prevent vertical transmission Pharmacodynamics 10
  • 11. Toxic Effects Of Drugs On The Embryo, Fetus, Or Neonate May vary • No effect. • Little • Serious- fetal toxicity • Spontaneous abortion • Death • Fetal malfunction • Fetal malformations. 11
  • 12. C. Predictable Toxic Effects i. Opioids : dependance , neonatal withdrawal syndrome, respiration depression ii. ACE inhibitors : renal damage iii. Diethylstilbestrol: adenocarcinoma of vagina after puberty Pharmacodynamics 12
  • 13. D. Teratogenic Drug Actions: Birth Defects • Incidence of major structural defects(abnormalities) is about 6% of all pregnancies. • 3% are caused by drugs or environmental factors/exposure • 3% have a genetic or unknown causes Pharmacodynamics 13
  • 14. • 1/2 of the birth defects are obvious at birth. • 1/2 of the birth defects aren’t discovered until later in life or discovered during an autopsy • Incidence of minor structural anomalies is not known. • Incidence of functional abnormalities is not known-growth restrictions, mental retardation, and learning disabilities • Some abnormalities have multiple causes- genetic factors, environmental factors, chemicals or drugs. 14
  • 15. Teratogenic Teratogenesis • Teras-”monster” • Gensis-”producing” • Birth defects/distortion of gross anatomy. • Examples- cleft lip/palate, clubfoot, neural tubal defects, missing or malformed limbs/fingers. • Now also- behavioral and/ or biochemical and/or physiological abnormalities. • Death of fetus & carcinogenic effect 15
  • 16. Mechanism of Teratogenesis • Direct effect on maternal tissue with secondary effect on fetus • Indirect-such as interfering with o2 or nutrients. • Teratogenesis maybe direct-malformations of structures. e.g. i. Vitamin A analogs (isotretinoin,etretinate) ii. Deficiency of a critical substance (folic acid causing neural tube defects) iii. Continues exposure to teratogen may produce cumulative effect (Fetal Alcohol Syndrome) 16
  • 17. Proving A Drug Is A Teratogen 3 Criteria must be met: • 1. Drug must cause a characteristic set of malformations with selectivity for certain organs • 2. It must act only during a specific window of vulnerability (organogenesis of target organ) • 3. The incidence of malformations should increase with increased dosage & duration of exposure. 17
  • 18. Fetal Effects From Drugs Depend On Several Factors • Time- when drug is taken in pregnancy. • Preimplantation/presomite period- conception to 2 week • High dose- maybe lethal/death/abortions. • Low dose-maybe nothing. As per time ….. 18
  • 19. ① 0-2 weeks-period of dividing zygote , implantation • Prenatal death may occur • Abortion may occur due to oxytosics e.g. ergot alkaloids, anti metabolites ② Embryonic period-3-8 weeks - First trimester • Gross malformations • E.G. One time exposure to thalidomide through 4th to 7th week-causes missing limbs(phocomalia). ③Fetal period-9-40 weeks(term) • Function problems rather than gross anatomy • Learning deficits &/or behavioral abnormalities 19
  • 20. 20
  • 21. 21
  • 22. 22
  • 24. • ⑤ During labor 24
  • 25. Others such as • Thrombocytopenia due to sensitization by thiazide diuretics when given to mother • Mercury may cause impaired brain development , cerebral palsy, mental retardation etc. • Other fetal defects due to effect of drug on spermatogenesis are suspected 25
  • 26. Why is identification of teratogenic agents sometimes difficult to identify? • Incidence of congenital anomalies is generally low. • Animal tests may not be reliable • Prolonged or increased exposure maybe required. • Effects maybe delayed or not reconized. • Behavioral effects are difficult to document. • Controlled experiments cannot be done on humans. 26
  • 27. • Documentation is incomplete • Only in a limited number of drugs is the teratogenic effects known or proven. • Lack of proof of teratogenicity does not mean a drug is safe in pregnancy • May mean there is a lack of research or information. 27
  • 28. How Is Data Collected On Drugs Which Cause Problems In Pregnancies? • No human experimentation • Systematic collection and analyzing of data on drugs taken by pregnant clients. • Reporting of information by health professionals. 28
  • 29. FDA category of drugs used in pregnancy 29
  • 30. Precautions While Prescribing During Reproductive Age & Pregnancy 1. In c/o contraception failure – Explain risk of drug already received & to continue pregnancy or abort 2. Similarly, in c/o post coital contraception 3. If a woman is being treated , explain risks to fetus & advise to avoid pregnancy till therapy completes 4. If a woman of reproductive age comes with any ailment pregnancy should be ruled out & then follow guideline as shown next 30
  • 31. A. If not pregnant i) Conception not desired : normal treatment ii) Conception desired: • Advise not to take any medication after last menstrual period • Advise folic acid & iron supplements • If diabetic start her on insulin • Avoid self treatment if ill, consult doctor 31
  • 32. B. If pregnant • Advise same as 4.A.ii in last slide • Avoid use of drug & treat minor problems without drugs • Strictly avoid proven teratogens i.e. Cat. X & D • If required prescribe proven safe drug • Use minimal dose for shortest period of time • If an unsafe or unproven drug has to be used than do α-fetoproteins at 16 weeks of gestation & high quality ultrasound at 18 weeks to asses anomalies 32
  • 33. Education Of Pregnant/Pre-pregnant • Provide accurate information with rationales • Information should be current and based on evidence. • Establish environment conducive to exchange of information - trust. • Potential harm/risks. Common substances & OTC drugs to avoid in pregnancy- ASA, alcohol, increased doses of multivitamins, caffeine, cigarette smoking, etc. • Avoid self treatment – OTCs • Support • Assist with coping if woman has taken a teratogenic agent..With guilt or fear…associated with drugs taken in pregnancy. 33
  • 34. Common Medications Safe In Pregnancy 1.GIT conditions: a) Nausea & vomiting: pyridoxine with or without doxylamine, meclizine, cyclizine, diphenhydramine Avoid- neuroleptics , metochlorpromide (safe in 3rd trimester) b) Constipation: mild purgative , lubricant purgative (less safe) Avoid- strong purgative as may cause abortion or premature labor pain 34
  • 35. c) Heart burn: milk of magnesia Avoid- anticholinergics d) Peptic ulcer: sucralfate, bismuthsubcitrate & H2 blockers 2.Hemopoetic Iron, folic acid no role of vit.B12 35
  • 36. 3.Infections a) Bacterial: i. UTI ampicillin, amoxycillin, cephalexin, cefadroxil, cefuroxime etc. Avoid-fluoroquinolones ii. Other β-lactum antibiotics (penicillin G, penicillin V), ampicillin, amoxycillin, cloxacillin) , cephalosporins (cephalexim, cefadroxil, cefuroxime, ceftriaxone) , macrolides(erythromycin avoid estolate salt, azithromycin). 36
  • 37. gentamycin & tobramycin only if serious infection b) Malaria: chloroquine, quinine (higher dose may induce labor), proguanil, pyrimethamine (with folic acid) c) Amoebiasis: metronidazole, diloxanide (avoid single large dose) d) Worm infestations: piperazine citrate, pyrantel pamoate, bephenium hydroxynaphthoate, praziquintal (teratogenic in animals not in humans) 37
  • 38. e) Fungal infections: miconazole, clotrimazole & nystatin f) HIV infection: none are safe but zidovudine and nevirapine are given to prevent vertical transmission g) Tuberculosis: INH and ethambutol, if 3rd needed rifampicin, pyrazinamide only in severe cases like meningitis 38
  • 39. 4. Endocrine disorders a) Diabetes mellitus: always use insulin b) Hypothyroidism: thyroxine c) Thyrotoxicosis: propylthiouracil d) Corticosteroid are highly teratanogenic and must be avoided 39
  • 40. 5. Cardiovascular disorders a) Hypertension: α-methyl dopa oral & hydralazine in emergency β blocker like labetolol (also can be given i.v.), atenolol b) Thromboembolic disease: LMWH (note just before labor) Avoid- warfarin 40
  • 41. 6. CNS disorders a) General anesthetics: thiopentone sodium & nitrous oxide b) Headache & Inflammation: paracetamol, codeine preparation Avoid- other NSAIDS aspirin can be used in lowest doses upto 2 weeks before EDD c) Epilepsy: Avoid-Na valproate, phenytoin d) Migraine: paracetamol, propranolol, amitryptyline 41
  • 42. e) Sedative : benzodiazepine; e.g. diazepam f) Antidepressant: amitryptyline, imipramine Avoid- Lithium (fetal cardiac anomalies) 7. Respiratory problems a) cough: codeine, dexomethorphan b) Bronchial asthma: β2 agonists (e.g. salbutamol), aminophyline, disodium cromoglycate 42
  • 43. 8. Others a) Corticosteroids must be avoided except at term for lung maturation with tocolytics b) Fat soluble vitamins may cause subaortic stenosis & craniofacial anomalies , so avoid c) Vaccines: only T.T. ; avoid live vaccines d) avoid indigenous drugs 43
  • 44. Drug Use During Lactation
  • 45. • Most drugs are excreted into breast milk • But they are less quantity • Because of large volume of distribution in mother’s body compared to small amount of milk • Lipophilic drugs are readily excreted also non plasma protein bound • pH of milk = 7.0 , slightly acidic • Mainly transported by passive diffusion • Adverse reaction in fetus due to i. slower elimination ( more accumulation) ii. Sensitive & idiosyncratic reaction 45
  • 46. • TRH & metochlorpramide ↑es lactation • Ergotamine & bromocriptine ↓es lactation used in loss of fetus or newborn & in hyperprolactinaemia • Most of the drugs & vaccines are safe • Drugs which are to be avoided or monitored are discribed next 46
  • 47. Drugs used during lactation & possible side effects 47
  • 48. Drug Use In Infants & Children
  • 49. Pharmacokinetics in Children 1. Absorption a. ↑ from skin due to thin stratum corneum & better hydration b. GIT: altered, low acidity, ↑ed gastric emptying time, ↑ed enterohepatic circulation, irregular peristalsis(PCM & phenobarbitone ↓ed & of penicillin G & ampicillin ↑ed ) c. Intramuscular & subcutaneous unpredictable because thin skeletal muscle mass & fat d. Low bile acid & lipase so less lipophilic drug absorption e. diarrhoea 49
  • 50. 2. Drug distribution a. More in c/o hydrophilic than adult because of higher percentage of body water (65-85%), also 40% is extra cellular in the neonate (aminogycoside) b. Less fat in pre term (1% ) than full term(15%) thus less lipophilic drug concentration in premature c. Less plasma protein available so more free drug , so more toxicity (diazepam) d. Competition with bilirubin for albumin may displace it , may cause kernicterus (sulfonamides) & vice versa (phenytoin) 50
  • 51. 3. Drug metabolism a. Less liver cytochrome P450 dependent activity , so chances of toxicity high e.g.chloramphenicol causing grey baby syndrome b. Table shows difference in half life in Neonate & adult p.s.phenobarbital & Phenytoin have low half life during infancy 51
  • 52. c. Enzyme induction Due to mother receiving drugs or child -enzyme induction may increase interaction -phenobarbitone is used to treat neonatal jaundice on the same principal * During toddlerhood metabolite rate of many drugs exceeds adult values . 52
  • 53. 4. Drug excretion a. GFR is less , so is tubular secretion, resulting in less renal clearance b. Normal clearance achieved at the age of 6-12 months c. Subsequently during toddlerhood it increases than adult value for some (e.g. for digoxin) d. So appropriate dose adjustment is necessary e. E.g. penicillin, ampicillin, aminoglycosides 53
  • 54. Pharmacodynamic alterations • Response of drug may be different in children than adults but mechanism remain same • Due to immature receptors or neurotransmitter system • e.g. glucocorticoids-premature epiphysial fusion; tetracyclines- malformed bone & teeth also staining of teeth, antihistaminics & barbiturates –excitement, amphetamine- ↓es abnormal hyperactivity 54
  • 55. Clinically important PDA can be closed with administration of indomethacin In case of fallot’s tetralogy administration of alprostadil (PGE1) is life saving 55
  • 56. Pediatric Dosage Forms & Compliance • Use of tablets is inconvenient & injections are rejected by children • So preferred formulations are liquid e.g. suspension, elixir, drops • Proper use should be instructed • Rejection, spitting & vomiting should be considered • Proper measurement • Suspensions to be shaken well before use • Reduce dosing errors • Encourage children to take medicine themselves 56
  • 57. Dose • Young’s rule: dose= Adult dose × Age(years) / Age + 12 • Clark’s rule: dose = Adult dose × Weight(kg) / 70 • Determination of drug dosage from surface area 57
  • 58. Drug Use In Geriatric Patients
  • 59. Geriatric (>65 years) patients have more chances of drug interactions & ADRs 1. Presence of multiple disease (avg. 5-8 drugs) 2. Sluggishness of various body functions 3. Reduced healthcare finance 4. Nutritional problem 5. Loss of spouse 6. Poor patient compliance due to poor understanding, confusion, forgetfulness, poor hearing, poor vision, physical disability 7. Pharmacological changes due to ageing 59
  • 60. Pharmacokinetic Changes a) Absorption • Slow due to ↓ed blood flow , ↓ed motility • Altered nutrition • Multiple OTCs b) Distribution • Reduced body weight • ↓ed body water, ↑ed body fat, ↓ed plasma proteins • So more free drug 60
  • 61. c) Biotransformation • ↓ed due to less liver mass, blood flow & reduced ability to recover from injury so • Phase I inactivation reduced by microsomal mixed function oxidases • No change in phase II reaction • Extensively first pass metabolized drug will have higher than normal conc. E.g. TCAs, neuroleptics, antidysrhythmic drugs • Less induction of hepatic microsomal enzyme so less interaction through there • Malnutrition & other diseases 61
  • 62. d) Excretion • ↓ed GFR, ↓ed tubular secretion, • No s.creat ↑ though, due to less muscle mass • Narrow therapeutic window drugs show toxicity e.g. lithium, digoxin, atenolol • Decrease respiratory capacity & more lung diseases so less excretion through lungs e.g. general anesthetics • Creat cl (ml/min)= (140-Age)×(weight kg) 72 × s.creat(mg/dl) 62
  • 63. Pharmacodynamic changes a) Response is decreased e.g. β agonists & β blockers , due to ↓ed no. of receptors b) Response is increased • More chance of postural/orthostatic hypotension due to reduced baroreceptor sensitivity • Drugs acting on CNS (like sedative-hypnotics) shows more response, more respiratory depression • Intolerance to digitalis & neuroleptic C) Drugs with anticholinergic activity may cause retention in elderly with BPH • Average BP increases • Temperature regulation is impaired 63
  • 64. Precautions While Prescribing To Elderly 1. Make sure of diagnosis & reuirement 2. Prescribe drug with minimal side effects 3. Prescribe minimum number of drugs (brown bag analysis) 4. Dose adjustment to minimal & mind hepatic or renal damage 5. Use suitable dosage form 6. Readable label , easy packing 7. ADR 8. Drug history including OTCs & herbal 64
  • 65. 9. Use FDCs where appropriate 10. Avoid drug interactions 11. Patient compliance 12. Discontinuation of drug is as important as starting , e.g. withdrawal syndromes, relapse of infection 65
  • 66. References • Basic and clinical pharmacology by Dr. Bertram G Katzung et al 12th edition • A complete textbook of medical pharmacology vol.II by Dr. S K Srivastava • Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th Edition) • www.cdc.gov/media/dpk/2013/docs/dpk- safe-meds-doc1.pdf 66
  • 67. 67